European Pharmaceutical Review

FEBRUARY 8, 2023

It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi sales will also be supplemented by the anticipated approval in chronic lymphocytic leukemia (CLL) in 2027, making it the first and only currently marketed CD19 CAR-T agent to penetrate the CLL market.

Marketing 98

Marketing Sales Physicians Patients 98

European Pharmaceutical Review

MAY 4, 2023

Martin Vogel, Janssen’s Therapeutic Area Lead Oncology for the Europe, Middle-East and Africa (EMEA) region shared with EPR what makes the BsMAb promising for treating this indication. Global Bispecific Antibodies for Cancer Market 2023-2027. Internet] Personalized Medicine Coalition. cited 2023Apr. Available from: [link] 8.

Food and Drug Administration 98

Food and Drug Administration Safety Patients Medicine 98

European Pharmaceutical Review

SEPTEMBER 7, 2023

Researchers can apply for grants and bid to take part in projects with certainty that the UK will be participating as a fully associated member until the deal reaches its end in 2027.

Government 97

Government Competition Pharmaceutical Manufacturing 97

European Pharmaceutical Review

SEPTEMBER 28, 2023

EMA prepares for winter antibiotic shortages PFAS restriction in pharmaceutical manufacturing In its current form, the procedure currently underway could lead to a ban on all PFASs by 2027, with very limited derogations, EFPIA acknowledged.

Pharmaceutical manufacturing 105

Pharmaceutical manufacturing Manufacturing Pharmaceutical Medicine 105

PM360

SEPTEMBER 21, 2023

CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. Some stakeholders have expressed concern that negotiation could lead to a reduction in drug innovation. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Medico Reach

DECEMBER 2, 2022

billion , and by 2027, it is expected to reach around an exciting amount of 115.1 from 2022 to 2027. CROs play a critical role in the pharmaceutical, biotech, and medical device industries to manage and lead their clinical trials now more than ever due to rapidly rising prices, regulations, and tighter deadlines.

Consulting 98

Consulting Specialization Medicine Medical 98

pharmaphorum

JANUARY 16, 2023

This is definitely not because all unmet need is addressed: the WHO reports that the three leading causes of death globally, and growing, are ischaemic heart disease, stroke, and chronic obstructive pulmonary disease. Alzheimer’s is currently the seventh-leading cause of death globally and growing fast.

FDA 98

FDA Healthcare Healthcare Medicine 98

Contrarian Sales Techniques

FEBRUARY 1, 2023

By focusing on the benefits, you are more likely to make a strong emotional connection with your prospects, which can lead to a sale. billion by 2027, growing at a CAGR of 7.7% from 2020 to 2027. For milk products, this could mean emphasizing the benefits of calcium for strong bones, or the protein content for building muscle.

Sales Strategy 52

Sales Strategy Sales Sales pitches Prospecting 52

pharmaphorum

JANUARY 9, 2023

BA is the leading cause of liver transplant in children and is caused by damaged or absent bile ducts, leading to build-up of bile in the liver and cirrhosis. FDA approval in this indication would unlock the additional $10 CVR payment, providing it takes place before the end of 2027.

Transportation 52

Transportation Sales Leads FDA 52

Pharmaceutical Technology

DECEMBER 16, 2022

This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. GlobalData’s report also covers a third pipeline candidate, quinagolide, a dopamine receptor antagonist being developed by Ferring Pharmaceuticals.

Marketing 59

Marketing Side effects Sales Safety 59

European Pharmaceutical Review

OCTOBER 12, 2023

So, by the time the facility is operational, anticipated for 2027, it has potential to transform access for clinical phase development of cell therapies in the region. According to Carlsen, developing “cell therapy products in large, consistent quantities” in Denmark is difficult, due to limited resources.

Pharmaceutical manufacturing 104

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 104

pharmaphorum

SEPTEMBER 22, 2022

The “US-first” mindset will lead to higher proportions of American patients in its clinical trials and investment in “capability and talent” in the US, where it aims to become a top-five player by 2027 – a big advance on its current 10th place. billion by 2024.

Management 52

Management Sales Patients Marketing 52

Medico Reach

SEPTEMBER 12, 2022

With an increase in market share, North America displays the most significant gastrointestinal endoscopic devices market growth , with trends indicating an annual growth rate of 6.95% from 2022 to 2027, expected to reach a value of 21.16 billion by 2027. The current valuation is 15.12 Final Thoughts.

Marketing 52

Marketing Doctors Training Medical 52

pharmaphorum

OCTOBER 6, 2022

Earlier this year, Novo Nordisk said that once-weekly injection Wegovy was emerging from a challenging early rollout beset by production problems, and is now expected to lead an obesity franchise at the company that could reap $3.7 billion in 2025 sales.

Sales 52

Sales Marketing FDA Leads 52

PM360

JULY 13, 2023

The future of healthcare is undoubtedly digital, and those who embrace this reality will certainly lead the way. MarketsandMarkets, “Polyols Market by Type, Application, End-use Industry, and Region – Global Forecast to 2027,” December 2022. References: 1.

Healthcare 98

Healthcare Healthcare Consulting Healthcare Provider 98

Medico Reach

FEBRUARY 8, 2023

AI can lead to faster research, combining and extracting data into usable formats, making clinical trials more efficient and saving time. billion by 2027. Global personalized medicine market forecast for the year 2027: Source The leading pharma firms are designing revolutionary, custom-made treatment methods.

Pharma 52

Pharma Medicine Marketing Prospecting 52

PM360

DECEMBER 14, 2022

billion euros into its new facility where it is planning to hire 400 and 500 new personal by 2027. the market is positioned to grow massively, projected to hit $147 billion by 2027. boasts 8,000 active licenses issued to cannabis businesses, leading the pack in countries with the largest markets. The company is pouring 1.2

Manufacturing 52

Manufacturing Medical Healthcare Healthcare 52

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. the enteric coating and the capsule dissolve.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105

Impetus Digital

MARCH 15, 2024

In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers (2).

Recruitment 78

Recruitment Healthcare Provider Patients Healthcare 78

European Pharmaceutical Review

MARCH 7, 2024

Last month, construction began on Europe’s first industrial-scale facility dedicated to the production of lead-212 based radioligand therapies. billion between 2022 to 2027. A report from Technavio suggests that due to trends in the nuclear medicine market such as isotope production, the radiopharmaceuticals market will grow by $4.61

Manufacturing 52

Manufacturing Food and Drug Administration Marketing Management 52

European Pharmaceutical Review

MARCH 4, 2024

percent through 2027. These actions occur at both the delivery site and other systemic locations, thereby promoting an immunogenic response that leads to cancer cell death. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

Food and Drug Administration 98

Food and Drug Administration Transportation FDA Medical 98

PM360

JUNE 29, 2022

markets by 2025 and 1,000 by 2027—and more than half of those practices are expected to be in medically underserved communities. The companies that can gain trust and deliver value have a chance to lead the pack. Additionally, Walgreens Boots Alliance (WBA) has made a $5.2

Retail 97

Retail Marketing Healthcare Healthcare 97

Infuse Medical

NOVEMBER 16, 2021

Despite this pivot, the objective remains the same – provide companies and exhibitors space and opportunity to engage with attendees, inform them about their brand and products, and generate leads.[/vc_column_text]. billion industry by 2027. Will there be a place for lead generation forms? vc_column_text].

Networking 52

Networking Media Leads Management 52

Clarivate

JULY 16, 2019

Here are some CX statistics that we have gathered and should get the attention of your CEO and CFO, and lead to further CX progress for your company. . By 2027, 75% percent of today’s S&P 500 companies will be replaced by new companies which are providing the best customer experience to their customers.

Competition 40

Competition Sales Leads Marketing 40

Clarivate

APRIL 24, 2023

After Walgreens upped its ownership stake in the primary-care company VillageMD from 30 to 63 percent and then announced plans to operate 1,000 clinics by 2027, the writing was on the wall: to stay competitive and manage costs in CVS’ newly integrated Aetna plan, CVS could benefit by making a larger bid for primary care of its own.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Clarivate

DECEMBER 6, 2023

from 2023 to 2030 and the AI market size is estimated to reach $407 billion by 2027. One attorney pointedly said, “Practitioners and clients need to lead the change instead of being pulled along by startups and new tech.” What is the current state of AI in IP? What does that mean for the IP legal industry?

Management 59

Management Professional Services Recruitment Government 59

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. It’s amazing we still separate the drug costs from overall healthcare costs,” Sontupe says.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Pharmaceutical Technology

JANUARY 10, 2023

There is a general decline in the major brands across the DPP-4I market, with sitagliptin (Januvia), the former market-leading T2D therapy, undergoing significant market decline with its impending patent expiry in 2027 and the development of sitagliptin generics in the Indian market.

Marketing 52

Marketing Physicians Leads Sales 52

LEVO Health

JULY 15, 2024

billion by 2027. Given their effectiveness, GLP-1 medications have gained popularity, leading to a surge in market demand. The GLP-1 market is rapidly expanding, driven by the increasing prevalence of obesity and diabetes and the efficacy of GLP-1 medications in managing these conditions. In 2021, the GLP-1 market was valued at $16.53

Marketing 52

Marketing Side effects Education Medical 52

Medico Reach

SEPTEMBER 19, 2022

Remote patient monitoring technology leads to effective treatment of lifestyle disorders. The global telemedicine market can reach up to USD 400 billion in 2027. In addition, telehealth enables lower rates of medical anxieties due to eliminating the need for physical visits. Enhanced Patient Outcomes. Conventional Mindset.

Healthcare 52

Healthcare Healthcare Healthcare Provider Physicians 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

SEPTEMBER 21, 2023

GoodRx is the leading platform 2 with the highest unaided awareness and trust across patients, physicians, and pharmacists 3 that Americans—regardless of insurance status—use across many phases of their healthcare journey. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.

Prescription 52

Prescription Medical Patients Distribution 52

Spotio

JULY 5, 2023

billion by 2027—a 48% jump from where the industry was last year, in 2022. The question can lead into your story, but the point is to get your prospect to participate. The only other thing you need is an industry-leading software application to help you source leads, canvas, and implement your sales sequences in a successful way.

Sales 40

Sales Prospecting Sales pitches Leads 40

Evolve Your Success

OCTOBER 31, 2023

By 2027, they are projected to be about $10 billion. Honestly, because it’s temporary, when we get ready to take out the temporary leads, some of the patients are like, “I don’t want that removed.” We’re living in those sci-fi movies that we watched when we were kids. Everybody’s buying now.

Engineering 52

Engineering Sales Medical sales Medical 52

PM360

OCTOBER 24, 2022

A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world with its medicines, and is developing a pipeline of innovative medicines. Amgen also offers a training curriculum to prepare new managers to lead and inspire their teams.

Pharma 40

Pharma Medicine Education Manufacturing 40

Star OUTiCO

FEBRUARY 18, 2022

The European Union’s EU4Health 2021-2027 budget, for example, allocates €5.3 AXiOM – our market-leading proprietary platform – has access to over 17 billion pieces of data and processes a further 20 million pieces each month, working to optimise our clients’ investments.

Pharma 52

Pharma Healthcare Healthcare Patients 52

Pharmaceutical Technology

APRIL 24, 2023

The rise of biologics In the lead-up to the 2020 boom, Swiss drugmaker Roche spent some $11 billion on biotechnology research and development in 2018. Syngene, which is among the leading CRDMOs in India, has biologics facilities that can produce a large array of products across mammalian and microbial platforms.

Manufacturing 52

Manufacturing Food and Drug Administration Biopharma Sales 52